ARTICLE
25 March 2026

CD Milan, March 13, 2026, Order On Application For Security For Costs, UPC_CFI_927/2025

BP
Bardehle Pagenberg

Contributor

BARDEHLE PAGENBERG combines the expertise of attorneys-at-law and patent attorneys. As one of the largest IP firms in Europe, BARDEHLE PAGENBERG advises in all fields of Intellectual Property, including all procedures before the patent and trademark offices as well as litigation before the courts through all instances.
Security for costs under Art. 69(4) UPCA / R. 158 RoP may be ordered where the claimant's own financial situation gives rise to a legitimate and real concern that a future costs award may not be recoverable or enforceable.
Italy Intellectual Property
Bardehle Pagenberg are most popular:
  • within Transport topic(s)

1 Key takeaway

Security for costs under Art. 69(4) UPCA / R. 158 RoP may be ordered where the claimant's own financial situation gives rise to a legitimate and real concern that a future costs award may not be recoverable or enforceable.

When assessing security for costs, the UPC looks at the financial position of the claimant itself, not at the financial strength of associated companies or the wider group absent guarantees or other special circumstances.

A claimant that does not substantively rebut the defendant's evidence on financial weakness risks having that financial position treated as undisputed under Rule 171.2 RoP.

Bare reliance on alleged SME or micro-enterprise status is insufficient to reduce security where the claimant does not substantiate the relevant criteria such as headcount, turnover and balance-sheet total.

The Court is not required to set security at the ceiling for recoverable costs; it may set a lower amount based on its own estimate of likely first-instance costs and proportionality considerations.

2 Division

Central Division Milan

3 UPC number

UPC_CFI_927/2025

4 Type of proceedings

Revocation action – decision on an application for security for legal costs under R. 158 RoP

5 Parties

Claimant:

La Siddhi Consultancy Ltd., United Kingdom

Defendants

1. Athena Pharmaceutiques SAS, France

2. Substipharm, France

6 Patent(s)

EP 3 592 333 (UP)

7 Body of legislation / Rules

Art. 69(4) UPCA

Art. 69(1) UPCA

R. 158.1 RoP

R. 171.2 RoP

UPC_CFI_927-2025_LaSiddhi v Athena_

Download

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More